Circulating free DNA concentration is an independent prognostic biomarker in lung cancer

Claire Tissot, Anne‐Claire Toffart, Stéphanie Villar, +8

European Respiratory Journal

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations

Claire Tissot, S. Couraud, Ronan Tanguy, +3

Lung Cancer

Somatic VariantMedicineBraf MutationsClinical CharacteristicsPathology +4

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Ali Chour, Julie Denis, Céline Mascaux, +27

Journal of Thoracic Oncology

MedicineLiver PhysiologyApoptosisPharmacologyBrief Report +9

Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)

Jessica Garcia, Julien Forestier, Eric Dusserre, +23

Oncotarget

PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis

Violaine Yvorel, Arnaud Patoir, François Casteillo, +7

PLoS ONE

OncologyP40 ExpressionTumor MicroenvironmentPd-l1 ExpressionMedicine +13

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting<i>ALK</i>and<i>ROS1</i>Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer

Laura Mezquita, Aurélie Swalduz, Cécile Jovelet, +27

JCO Precision Oncology

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i> -Mutant Metastatic Non–Small Cell Lung Cancer

Sandra Ortiz‐Cuaran, Laura Mezquita, Aurélie Swalduz, +31

Clinical Cancer Research

EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer

S. Lainez, Claire Tissot, Michèle Cottier, +1

Respiration

Lymphoid NeoplasiaCancer EvolutionNivolumab TreatmentMedicineMultiple Pulmonary Nodule +11

Histopathological subtyping is a prognostic factor in stage IV lung adenocarcinoma

Vanessa Da Cruz, Violaine Yvorel, François Casteillo, +7

Lung Cancer

Prognostic FactorMedicineHistopathologyPathologyBronchial Neoplasm +6

Profiling of circulating tumor DNA in plasma of non‐small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells

Jessica Garcia, Anne‐Sophie Wozny, Florence Geiguer, +14

Cancer Medicine

ImmunologyPathologyWhole BloodNucleic Acid BiomarkersTumor Biology +17